Breaking News

Mpox is still here.

June 7, 2024
Annalisa-Merelli-avatar-teal
General Assignment Reporter

Buongiorno! Remember mpox? Two years after the U.S. outbreak, cases are few — but not gone, and the CDC is warning that the low vaccination coverage and lack of awareness about the disease may result in further spread, particularly among men who have sex with men, who are at the highest risk of infection. Plus in the DRC, where mpox has caused 1,000 deaths since 2023, researchers are monitoring a different clade from the one that caused the American outbreak that seems to be more transmissible — and if Covid taught us anything, it's that viruses like to travel. 

infectious diseases

Mpox is still circulating among communities at risk in the U.S.

GettyImages-1242547535

Ernesto Benavides/AFP via Getty Images

Cases of mpox have declined sharply compared to the outbreak in 2022, but men who have sex with men continue to experience cases, according to new data published yesterday by the Centers for Disease Control and Prevention

The cases were tracked in a UCLA-led multi-site study, which enrolled 196 people, including 45% women and 20% children. No one in those two groups reported any cases, and overall only three cases were identified (1.5%). All were among men who reported having sex with multiple men in the month prior, and not being vaccinated against mpox. But the small incidence shouldn't lead to complacency — quite the opposite, experts say. 

Researchers are monitoring a different mpox clade — think strain — that has triggered a large outbreak in the Democratic Republic of the Congo. This version of the virus, known as clade 1, seems to be more transmissible and is known to cause more serious disease than the clade 2b viruses that have been circulating internationally since at least 2022. The authors said health professionals should be on the lookout for mpox cases, in particular among at-risk people, considering vaccination coverage is still low (only 23% of people at risk received both doses, according to the most recent CDC data available), and so is awareness of mpox symptoms and modes of transmission. 


biotech

Biotech companies are fretting about U.S. legislation to limit their business with China

A bill in Congress would restrict U.S. biotech companies from doing business with certain Chinese firms and suppliers. And while it isn't yet a law, it's already having a significant impact on the industry, report my colleagues Jonathan Wosen and Meghana Keshavan, who attended the yearly meeting of BIO, biotech's biggest trade group. 

While the legislation may pose a challenge for American companies that may have to change suppliers — and potentially face increased costs — it's good news for at least two groups: U.S.-based suppliers (one executive said business has gone "through the roof"), and Chinese companies not named in the bill. European countries may also be well-positioned to pick up business otherwise destined to China. Read more here to see how the looming bill is changing biotech business dynamics. 


long covid

We may soon start seeing the impact of long Covid on disability claims 

Despite the large number of people affected by what has been labeled a "mass-disabling event" — Covid — applications for disabilities have been pretty stable so far, even as more people self-identify as disabled, and close to 14 million Americans suffer from long Covid, writes STAT's Isabella Cueto. 

But a new report commissioned by the Social Security Administration says things may change, and more people may apply for disability benefits due to long Covid. "We conclude that long Covid is a real condition," said the chair of the committee that drafted the report, which provided guidance on indicators that are relevant to diagnose long Covid, which can manifest in a variety of symptoms, or present as different diseases, such as chronic fatigue, or cardiovascular issues. 

This makes it difficult to apply for disability benefits for long Covid, which hardly fits any of the standardized requirements, though the report's findings could help patients establish their disability status. More here. 

 



Q&A

Stephen Quake talks about his career in life science, and the Chan Zuckerberg Initiative's ambitious goals 

Steve-Quake-Headshot-2022-3

Chan Zuckerberg Initiative

How is the Chan Zuckerberg Initiative going to "to help cure, prevent, or manage all disease by the end of the century"? My colleague Jonathan Wosen asked CZI's head of science, Stephen Quake. 

In an interview, they discussed — among other things — how the sight of his wife getting an amniocentesis got Quake, then a theoretical physicist, to turn to life sciences, how his physics background helped him improve prenatal testing, and what made him want to join CZI. And on the question of how to achieve such a bold goal within a century, his answer is: by bringing along the rest of the scientific community. "We're not going to do it ourselves, that's for sure!" he said. More here, including the disclosure of the location of CZI's headquarters.


first opinion

Medical debt relief isn't a silver bullet

Medical debt in the U.S. is a huge, ubiquitous problem, affecting 40% of American adults and amounting to $220 billion a year. But a recent study showed that simple debt relief programs don't seem to cut it: Paying off a patient's debt didn't increase the use of health care services, or reduce financial stress; in fact, some of the beneficiaries of debt relief interventions fared worse than before.

While counterintuitive, these results are telling, and highlight the limited impact of debt forgiveness, writes Katherine Hempstead, a senior policy adviser at the Robert Wood Johnson Foundation, in First Opinion. 

Debt relief programs don't actually address the mechanism by which debt is created, and instead exploit the same incentives that motivate collection agencies. But in order to have significant improvement in the impact of medical debt, systemic reform is inevitable, and debt relief is just a Band-Aid, Hempstead says. Read more.


More around STAT
Check out more exclusive coverage with a STAT+ subscription
Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

What we're reading

  • 'Unusual' cancers emerged after the pandemic. Doctors ask if Covid is to blame. Washington Post
  • Do digital physical therapy solutions work? New report has some insights, STAT

  • As hospitals grow, so does your bill, Wall Street Journal
  • 100,000 models show that not much was learned about stopping the Covid-19 pandemic, STAT

  • How do we know when to pee? Smithsonian Magazine


Thanks for reading! More next week,

Nalis


Enjoying Morning Rounds? Tell us about your experience
Continue reading the latest health & science news with the STAT app
Download on the App Store or get it on Google Play
STAT
STAT, 1 Exchange Place, Boston, MA
©2024, All Rights Reserved.

No comments